Solu-Cortef
Bronchopulmonary Dysplasia
National Center for Research Resources (NCRR)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Bronchopulmonary Dysplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE National Center for Research Resources (NCRR) | Phase 3 | B |
Helium Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
PERFLUTREN Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
XENON Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
Sonovue Thunder Bay Regional Health Research Institute | Early Phase 1 | C |
RED BLOOD CELLS Hospital Clinic of Barcelona | N/A | D |
Cord Blood Red Blood Cells Hospital Clinic of Barcelona | N/A | D |
Same molecule, other indications
Solu-Cortef is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →